By transfecting HNSCC cells with an adenoviral vector containing a mutated RAD50 gene (ad-RAD50), researchers observed a decrease in cell proliferation, which was further enhanced when combined with cisplatin both in vitro and in vivo [154]. This evidence concerns the gene RAD50 and head and neck squamous cell carcinoma.